Overview

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability of single increasing doses of intravenously administered rolapitant in healthy male and female subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Tesaro, Inc.

Treatments:

8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one
Rolapitant